Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162438 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3CDK1 | |
| SCHEMBL4528273 | 0.88 | CDK1 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CDK1 | |
| SCHEMBL4721289 | 0.88 | CDK1 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CDK1 | |
| SCHEMBL29618159 | 0.88 | CDK1 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CDK1 | |
| SCHEMBL13769145 | 0.88 | CDK1 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CDK1 | |
| SCHEMBL30316026 | 0.85 | SMPD3 (0.47) | CHRNB2CHRNA4CDK1CDK2SMN1; SMN2 | |
| SCHEMBL17796348 | 0.85 | SMPD3 (0.47) | CHRNB2CHRNA4CDK1CDK2SMN1; SMN2 | |
| SCHEMBL17799085 | 0.85 | SMPD3 (0.47) | CHRNB2CHRNA4CDK1CDK2SMN1; SMN2 | |
| SCHEMBL17054803 | 0.85 | SMPD3 (0.47) | CHRNB2CHRNA4CDK1CDK2SMN1; SMN2 | |
| SCHEMBL30316041 | 0.85 | SMPD3 (0.47) | CHRNB2CHRNA4CDK1CDK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | CHRNB2 1857/4885CHRNA4 1717/4885CHRNB4 1704/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | CHRNB2 1857/4885CHRNA4 1717/4885CHRNB4 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.